Who makes Part1 : OPS-2071?

Part1 : OPS-2071 is developed by Korea Otsuka Pharmaceutical Co., Ltd..

What development phase is Part1 : OPS-2071 in?

Part1 : OPS-2071 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Part1 : OPS-2071

Korea Otsuka Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	Part1 : OPS-2071
Sponsor	Korea Otsuka Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part1 : OPS-2071 CI brief — competitive landscape report
Part1 : OPS-2071 updates RSS · CI watch RSS
Korea Otsuka Pharmaceutical Co., Ltd. portfolio CI